Total raised
$217.0M
Last stage
Series A
Investors
Sanjaya Singh
PhD in molecular biology; co-inventor of Risankizumab (Skyrizi) and other immunology/oncology compounds; former Global Head of Janssen Biotherapeutics at J&J; founded Third Arc Bio in 2022.
LinkedInPeter F. Lebowitz
MD, PhD; joined Third Arc Bio as CEO in January 2024; former Global Head of Oncology R&D at Johnson & Johnson, where he oversaw 13 major drug approvals.
LinkedInJoe Erhardt
PhD; joined Third Arc Bio in 2023; formerly VP and Global Head of Oncology Discovery and External Innovation at Johnson & Johnson.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.